Clinical Trial Update: PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of ponatinib and 5-azacitidine in chronic myelogenous leukemia in accelerated phase or myeloid blast crisis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelogenous Leukemia in Accelerated Phase
• Myelogenous Leukemia in Myeloid Blast Crisis

Drugs mentioned

• 5-Azacitidine (azacitidine)
• Ponatinib (ponatinib)

Snippet

Sponsor: Versailles Hospital | Conditions: CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE, CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS | Phase 2 | Status: UNKNOWN